强化血压控制与IgA肾病进展:边缘结构模型队列研究
该队列研究纳入1530例IgA肾病患者,采用边缘结构模型分析基线及时间更新血压与复合肾脏结局(ESKD或eGFR下降30%)的关系。中位随访43.5个月,367例(24.0%)发生复合结局。以时间更新收缩压110-119 mmHg为参照,<110、120-129、130-139、≥140 mmHg的风险比分别为1.48、1.13、2.21、2.91,呈U型关联,结论提示治疗期强化降压可能延缓肾病进展但需考虑低血压风险。
要点
- 时间更新收缩压与复合肾脏结局呈U型关联,110-119 mmHg为参照。
- 收缩压<110 mmHg风险比为1.48,高于参照组。
- 蛋白尿≥1 g/d且eGFR≥60者U型趋势更明显。
核心结论
- 在IgA肾病患者中,治疗期间强化血压控制可能延缓肾病进展,但低血压的潜在风险仍需考虑。
研究设计与样本
- 北京大学第一医院纳入1530例IgA肾病患者的队列研究,采用多变量因果风险模型和边缘结构模型分析基线及时间更新血压与复合肾脏结局的关系。
主要发现
- 中位随访43.5个月(四分位距27.2-72.7),367例(24.0%)发生复合肾脏结局。
- 基线血压与复合结局无显著关联。
- 以时间更新收缩压110-119 mmHg为参照,<110、120-129、130-139、≥140 mmHg的风险比(95%CI)分别为1.48(1.02-2.17)、1.13(0.80-1.60)、2.21(1.54-3.16)、2.91(1.94-4.35)。
- U型趋势在蛋白尿≥1 g/d且eGFR≥60 mL/min/1.73 m²的患者中更明显。
- 分析时间更新舒张压后未观察到类似趋势。
关键数值与推荐
- 复合肾脏结局定义为发生终末期肾病(ESKD)或估算肾小球滤过率(eGFR)下降30%。
- 当前指南推荐慢性肾脏病患者收缩压低于120 mmHg。
临床怎么用
- 治疗期强化血压控制可能延缓IgA肾病进展,但需考虑低血压的潜在风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In chronic kidney disease, current guidelines recommend systolic blood pressure (SBP) below 120 mmHg. However, the renoprotective effect of intensive blood-pressure (BP) lowering on immunoglobulin A nephropathy (IgAN) remains undetermined. We aimed to determine the effect of intensive BP control on the progression of IgAN. METHODS: At Peking University First Hospital, 1530 patients with IgAN were enrolled. An examination of the relationship between baseline and time-updated BP and composite kidney outcomes, defined as development of end-stage kidney disease (ESKD) or a 30% decline in estimated glomerular filtration rate (eGFR), was conducted. Baseline and time-updated BPs were modeled using multivariate causal hazards models and marginal structural models (MSMs). RESULTS: In a median follow-up of 43.5 (interquartile range 27.2, 72.7) months, 367 (24.0%) patients experienced the composite kidney outcomes. No significant associations were found between baseline BP and the composite outcomes. Using MSMs with time-updated SBP for analysis, a U-shaped association was found. In reference to SBP 110-119 mmHg, hazard ratios (95% confidence intervals) for the SBP categories <110, 120-129, 130-139 and ≥140 mmHg were 1.48 (1.02-2.17), 1.13 (0.80-1.60), 2.21 (1.54-3.16) and 2.91 (1.94-4.35), respectively. The trend was more prominent in patients with proteinuria ≥1 g/day and eGFR ≥60 mL/min/1.73 m2. After analyzing time-updated diastolic BP, no similar trend was observed. CONCLUSIONS: In patients with IgAN, intensive BP control during the treatment period may retard the kidney disease progression, but the potential risk of hypotension still needs to be considered.
引用
- Tang C, Chen P, Si FL, et al. Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models. Nephrol Dial Transplant. 2023. PMID: 37391382. doi:10.1093/ndt/gfad139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。